Profile
Heather Harte-Hall currently works at Society of Corporate Compliance & Ethics, as Member and Cabaletta Bio, Inc., as Chief Compliance Officer from 2021.
Ms. Harte-Hall also formerly worked at Adaptimmune Therapeutics Plc, as Head-Clinical Quality & Compliance.
Ms. Harte-Hall received her undergraduate degree from Saint Leo University, Inc. and graduate degree from Capella University LLC.
Heather Harte-Hall active positions
| Companies | Position | Start |
|---|---|---|
| CABALETTA BIO, INC. | Compliance Officer | 2019-02-28 |
Society of Corporate Compliance & Ethics
Society of Corporate Compliance & Ethics Miscellaneous Commercial ServicesCommercial Services Provide training, certification, networking, and other resources to compliance officers & staff | Corporate Officer/Principal | - |
Former positions of Heather Harte-Hall
| Companies | Position | End |
|---|---|---|
| ADAPTIMMUNE THERAPEUTICS PLC | Compliance Officer | - |
Training of Heather Harte-Hall
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Society of Corporate Compliance & Ethics
Society of Corporate Compliance & Ethics Miscellaneous Commercial ServicesCommercial Services Provide training, certification, networking, and other resources to compliance officers & staff | Commercial Services |
Saint Leo University, Inc.
Saint Leo University, Inc. Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Capella University LLC
Capella University LLC Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Adaptimmune Therapeutics Plc
Adaptimmune Therapeutics Plc BiotechnologyHealth Technology Manufactures vaccines and cancer immunotherapy products | Health Technology |
Cabaletta Bio, Inc.
Cabaletta Bio, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which discovers and develops engineered cell therapies for B cell-mediated autoimmune diseases | Health Technology |
- Stock Market
- Insiders
- Heather Harte-Hall
















